Overall exports jumped almost 30%

Shown above is the head office of Celltrion in South Korea. [Photo courtesy of Celltrion]
Shown above is the head office of Celltrion in South Korea. [Photo courtesy of Celltrion]

Celltrion’s export to the United States surged dramatically this year, emerging as one of the strongest growth stories in Korea’s pharmaceutical and biotech sector. 

According to new industry data compiled as of the third quarter on Nov. 24, 18 of the country’s 20 major listed pharmaceutical and biotech firms saw their cumulative export results rise year over year.

And Celltrion’s expansion was among the most striking, with U.S. exports growing more than threefold compared to the same period last year.

The South Korean biopharmaceutical company’s U.S. export volume jumped from 77.8 billion won ($53 million) in last year’s third-quarter cumulative total to 265 billion won ($180 million) this year. 

In just nine months, Celltrion has already far exceeded its entire U.S. export figure for the previous year, which stood at 106.8 billion won ($72 million). 

Market observers attribute this rapid increase to Korean pharmaceutical companies’ strategy of securing inventory in the U.S. ahead of potential tariff risks.

Celltrion’s export growth was not limited to the United States. 

Shipments to the global markets jumped 29 percent during the first nine months of this year compared to the corresponding period of 2024.

키워드
#Celltrion’s export to the United States surged dramatically this year #emerging as one of the strongest growth stories in Korea’s pharmaceutical and biotech sector. According to new industry data compiled as of the third quarter on Nov. 24 #18 of the country’s 20 major listed pharmaceutical and biotech firms saw their cumulative export results rise year over year. And Celltrion’s expansion was among the most striking #with U.S. exports growing more than threefold compared to the same period last year. The company’s U.S. export volume jumped from 77.8 billion won ($53 million) in last year’s third-quarter cumulative total to 265 billion won ($180 million) this year. In just nine months #Celltrion has already far exceeded its entire U.S. export figure for the previous year #which stood at 106.8 billion won ($72 million). Market observers attribute this rapid increase to Korean pharmaceutical companies’ strategy of securing inventory in the U.S. ahead of potential tariff risks. Celltrion’s export growth was not limited to the United States. Shipments to the global markets jumped 29 percent during the first nine months of this year compared to the corresponding period of 2024. #Celltrion
이 기사를 공유합니다
Copyright © The Korea News Plus